CLS participates in BIO 2017 in San Diego, USA, with support from the EU SME Instrument - Overseas Trade Fairs Participation Program
Clinical Laserthermia Systems (CLS) (publ), will be participate in the BIO International Convention 2017 in San Diego, USA. Out of 10 000 applicants CLS has been chosen, as one of fifteen European ”Champion companies”, to receive support, in terms of money and services, from the European Union’s ”SME Instrument – Overseas Trade Fairs Participation Program”, corresponding to a value of about 5000 Euro.
- This grant from the EU makes it possible for CLS to participate in the BIO International Convention, one of the world’s largest B2B meetings in the Biotech industry. By attending BIO 2017 we will in an efficient manner get in contact with academic as well as commercial players in primarily the area of immuno-oncology, said Dan Mogren, CCO of CLS. EU’s SME Instrument program is opening doors that smaller companies could otherwise have difficulties to access, said Dan Mogren.
CLS develops and markets the TRANBERG®|Thermal Therapy System, as well as disposable materials and methods for heat-induced immunotherapy for safe and gentle treatment of cancerous tumors. BIO International Convention (Biotechnology Industry Organization) is a large venue covering several areas such as Life Science, biology, biosciences, drug discovery, genomics, bioengineering, cell therapy, pharma industry and bio-manufacturing. The conference is held in San Diego, USA, 19 – 21 June and CLS will exhibit in the SME Instrument – Overseas Trade Fairs pavilion booth #5837.
Read more about BIO 2017
This information is such that Clinical Laserthermia Systems AB (publ) is required to publish pursuant to the EE Market Abuse Directive. The contact person arranged for the release of this information on 30 March 2017.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se
Clinical Laserthermia Systems AB (publ) develops and markets a safe, gentle, effective, and clinically documented therapy for treatment of solid cancer tumors. The product is based on immunostimulating interstitial laser thermotherapy (imILT). CLS is listed on Nasdaq First North under the stock symbol CLS B. Certified Adviser is Västra Hamnen Corporate Finance. More information is available on the Company's website www.clinicallaser.se